✦ LIBER ✦

Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia

✍ Scribed by Jamieson, Katarzyna; Odenike, Olatoyosi

Book ID: 119944849
Publisher: Informa plc
Year: 2012
Tongue: English
Weight: 322 KB
Volume: 13
Category: Article
ISSN: 1465-6566
DOI: 10.1517/14656566.2012.724061

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

5-Azacytidine treatment for relapsed or

5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy

✍ Ivanoff, Sarah; Gruson, Berengere; Chantepie, Sylvain P.; Lemasle, Emilie; Merlu 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Early versus Late Preemptive Allogeneic

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia

✍ Chen, George L.; Liu, Hong; Zhang, Yali; Thomas, Julie; Ross, Maureen; Wang, Eun 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 667 KB

FLAG-IDA in the treatment of refractory/

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience

✍ D. Pastore; G. Specchia; P. Carluccio; A. Liso; A. Mestice; R. Rizzi; G. Greco; 📂 Article 📅 2003 🏛 Springer 🌐 English ⚖ 116 KB

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute myeloid leukemia with diaziquone and mitoxantrone: A CALGB phase I study

✍ Philip C. Amrein; Roger B. Davis; Robert J. Mayer; Charles A. Schiffer 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

International Randomized Phase III Study

International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia

✍ Roboz, G. J.; Rosenblat, T.; Arellano, M.; Gobbi, M.; Altman, J. K.; Montesinos, 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 288 KB

Mitoxantrone in the treatment of relapse

Mitoxantrone in the treatment of relapsed and refractory acute leukemia

✍ P. Meyer; A. D. Ho; G. Ehninger; I. Mjaaland; E. Heidemann; E. Seither 📂 Article 📅 1985 🏛 Springer US 🌐 English ⚖ 245 KB

Twenty-four patients with acute leukemia or blast crisis (BC) of chronic myelocytic leukemia (CML) in relapse or refractory to standard chemotherapy, were eligible for treatment with mitoxantrone. Mitoxantrone (Novantrone| dihydroxyanthracenedione) was administered in a dose of 8-13 mg/m 2 on five c